94 articles with Boehringer Ingelheim
11/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Boehringer Ingelheim Ltd and Eli Lilly Canada Inc. are pleased to announce that Jardiance® has been granted marketing authorization by Health Canada as a treatment for heart failure with reduced ejection fraction, as an adjunct to standard of care therapy, in adults with an eGFR as low as 20 mL/min/1.73 m2.
Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia
Together, Boehringer Ingelheim and King’s College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Boehringer Ingelheim will be commencing a new collaboration with Thoeris GmbH with the goal of advancing a first-in-class approach for the treatment of urea cycle disorders (UCDs) independent of the underlying monogenetic cause
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
Boehringer Ingelheim marks the World Health Summit 2021 by announcing updates to its strategic approach to sustainable development
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium and Oxford Biomedica, announced that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners to progress and further accelerate the development of a potential, new treatment option for patients with CF.
Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.
Boehringer Ingelheim announced the U.S. Food and Drug Administration approved the supplemental Biologics License Application for Cyltezo® as the first Interchangeable biosimilar with Humira®.
Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification to encourage healthcare professionals (HCPs) to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) conditions
Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health
Boehringer Ingelheim and Invetx are pleased to announce they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody (mAb) biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor
G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team.
There were a fair number of clinical trial announcements last week. Here’s a look.
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.
CureVac has revealed in its latest financial report that its lung cancer program with German biotechnology company Boehringer Ingelheim has been terminated.
GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to PatientsPotential to provide approximately $15 million a year in savings for life-enhancing medications
GoodRx , Inc. (Nasdaq: GDRX), America’s leading resource for healthcare savings, and Boehringer Ingelheim , a privately owned, leading global biopharmaceutical company, today announced a new joint effort to increase access to patient savings programs on the GoodRx platform.
In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before.
ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals, announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.
Boehringer Ingelheim Animal Health USA Inc. has appointed Bryan Haardt as General Manager of Pawru, Inc., a Boehringer Ingelheim company that facilitates collaborative pet care by connecting veterinary professionals and pet owners on an innovative digital platform.